Print
Email
Print Edition Stories
MHT's Marc Songini: RI plans launch of cord blood center
MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban
Rodney Brown on NECN: Hacking into medical devices
Flash Slideshow: Mass High Tech All-Stars Thought Leadership Roundtable
Streaming Video: Mass High Tech All-Stars Thought Leadership Roundtable
Cambridge-based Alnylam Pharmaceuticals Inc. has received a notification of “intent to grant” a patent from the European Patent Office for Alnylam’s Tuschl I patent series. The new patent would be the first to be granted in the European Union from the Tuschl I patent series, and includes 19 claims broadly covering the use of double stranded RNAs (dsRNAs) for RNAi, according to Alnylam.
The Tuschl I patent claim (EP1309726) broadly covers RNAi methods, including methods of reducing the expression of a mammal or viral gene with dsRNAs between 21 and 23 nucleotides in length. The patent also includes claims covering methods of examining the function of a gene, as well as the use of both unmodified and chemically modified dsRNAs. The company expects the patent to be granted in approximately four months. Alnylam is the exclusive licensee of the ownership interests of the Max Planck Society, MIT, and Whitehead Institute for Biomedical Research, in the Tuschl I patent series for RNAi therapeutics.
In March, Alnylam and MIT MIT-show-data-on-new-nanoparticles.html" target="_blank">reported on new research around a class of organic molecules that can be formed into nanoparticles. Lipidoids are a new class of lipid-based molecules that can be formed into new nanoparticle compounds for systemic delivery of RNAi treatments.
RSS Feeds
Comments
Please Login/Register to post comments.
No comments have been added or approved.